Fig. 3

(A) The efficacies of various treatment strategies for patients with secondary BRAF variants following resistance to prior TKIs. Chemotherapy-based regimens are shown by the red bar; Multi-target combination therapy is indicated by the blue bar. Continuing current targeted therapy is indicated by the green bar. Targeted therapy combined with local therapy is indicated by the purple bar. 1 represents the use of first-generation targeted drugs. 2 represents the use of second-generation targeted drugs. 3 represents the use of third-generation targeted drugs.1/2 is indicated by the orange bar. 3 is indicated by the yellow bar. PD, progressive disease; PR, partial response; SD, stable disease; The texts on the side of the figure represent types of BRAF variations. (B) Kaplan–Meier survival curves and At-Risk Table for global OS after treatment for NSCLC patients with secondary BRAF alterations by group.